biotech · Duchenne Muscular Dystrophy · Duchenne muscular dystrophy · SLDB
Solid Biosciences
Solid Biosciences is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker SLDB. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Duchenne muscular dystrophy, Glioblastom
500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US HQ
2013 Founded
155 Employees
Public company Type
SLDB · NYSE Ticker
Company details
- Status
- Public
- HQ
- 500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US
- Founded
- 2013
- Employees
- 155
- Programs
- 16
- Drugs
- 20
- Patents
- 2
SGT-001
Phase 2 · gene therapy · Duchenne Muscular Dystrophy
SGT-001 for Duchenne Muscular Dystrophy is a Phase 2 program (gene_therapy) at Solid Biosciences with 1 ClinicalTrials.gov record(s).
Internal code GX1001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Solid Biosciences
- Phase
- Phase 2
- Modality
- gene_therapy
- Indication
- Duchenne Muscular Dystrophy
- Status
- active
- Trials
- 1